Cargando…

Plasma protein alterations in the refractory anemia with excess blasts subtype 1 subgroup of myelodysplastic syndrome

BACKGROUND: Refractory anemia with excess blasts subtype 1 (RAEB-1) is a subgroup of myelodysplastic syndrome. It represents a heterogeneous group of oncohematological bone marrow diseases, which occur particularly in elderly patients. The aim of this proteomic study was to search for plasma protein...

Descripción completa

Detalles Bibliográficos
Autores principales:	Májek, Pavel, Reicheltová, Zuzana, Suttnar, Jiří, Čermák, Jaroslav, Dyr, Jan E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3470985/ https://www.ncbi.nlm.nih.gov/pubmed/22568928 http://dx.doi.org/10.1186/1477-5956-10-31

Ejemplares similares

Proteome Changes in the Plasma of Myelodysplastic Syndrome Patients with Refractory Anemia with Excess Blasts Subtype 2
por: Majek, Pavel, et al.
Publicado: (2014)

Plasma proteome changes associated with refractory anemia and refractory anemia with ringed sideroblasts in patients with myelodysplastic syndrome
por: Májek, Pavel, et al.
Publicado: (2013)

Plasma proteome changes associated with refractory cytopenia with multilineage dysplasia
por: Májek, Pavel, et al.
Publicado: (2011)

Plasma Protein Biomarker Candidates for Myelodysplastic Syndrome Subgroups
por: Majek, Pavel, et al.
Publicado: (2015)

Plasma proteome changes in cardiovascular disease patients: novel isoforms of apolipoprotein A1
por: Májek, Pavel, et al.
Publicado: (2011)

Proteome changes in platelets activated by arachidonic acid, collagen, and thrombin
por: Májek, Pavel, et al.
Publicado: (2010)

Peripheral Blood Mononuclear Cell Proteome Changes in Patients with Myelodysplastic Syndrome
por: Pecankova, Klara, et al.
Publicado: (2015)

Plasma Levels of Aminothiols, Nitrite, Nitrate, and Malondialdehyde in Myelodysplastic Syndromes in the Context of Clinical Outcomes and as a Consequence of Iron Overload
por: Pimková, Kristýna, et al.
Publicado: (2014)

Posttranslational Modifications of Red Blood Cell Ghost Proteins as “Signatures” for Distinguishing between Low- and High-Risk Myelodysplastic Syndrome Patients
por: Pecankova, Klara, et al.
Publicado: (2017)

Enhanced levels of asymmetric dimethylarginine in a serum of middle age patients with myelodysplastic syndrome
por: Štikarová, Jana, et al.
Publicado: (2013)

A New Approach for the Diagnosis of Myelodysplastic Syndrome Subtypes Based on Protein Interaction Analysis
por: Chrastinová, Leona, et al.
Publicado: (2019)

Bullous Pemphigoid in an Elderly Patient with Myelodysplastic Syndrome and Refractory Anemia Coupled with Excess of Blast
por: Lee, Yin Yin, et al.
Publicado: (2011)

Improved Coomassie Blue Dye-Based Fast Staining Protocol for Proteins Separated by SDS-PAGE
por: Májek, Pavel, et al.
Publicado: (2013)

Identification of genes underlying different methylation profiles in refractory anemia with excess blast and refractory cytopenia with multilineage dysplasia in myelodysplastic syndrome
por: Lee, Suee, et al.
Publicado: (2012)

Proteome changes of plasma-derived extracellular vesicles in patients with myelodysplastic syndrome
por: Pecankova, Klara, et al.
Publicado: (2022)

Severe atypical herpes zoster as an initial symptom of fatal myelodysplastic syndrome with refractory anemia and blast excess (RAEB II)
por: Wollina, Uwe, et al.
Publicado: (2017)

Localized ecthyma gangrenosum without sepsis in a neutropenic patient with a myelodysplastic syndrome—Refractory anemia with excess blasts type 2
por: Zanella, Anaïs, et al.
Publicado: (2019)

Impact of posttranslational modifications on atomistic structure of fibrinogen
por: Sovová, Žofie, et al.
Publicado: (2020)

Extension of the Human Fibrinogen Database with Detailed Clinical Information—The αC-Connector Segment
por: Sovova, Zofie, et al.
Publicado: (2021)

Molecular Dynamic Simulations Suggest That Metabolite-Induced Post-Translational Modifications Alter the Behavior of the Fibrinogen Coiled-Coil Domain
por: Sovova, Zofie, et al.
Publicado: (2021)

Proteomic Case Studies of MDS in Progression: Heterogeneity and More Heterogeneity
por: Pecankova, Klara, et al.
Publicado: (2022)

Effects of 5-azacytidine on natural killer cell activating receptor expression in patients with refractory anemia with excess of blasts
por: Costello, Régis T., et al.
Publicado: (2015)

Pseudomonas aeruginosa ventriculitis following pancytopenia due to myelodysplastic syndrome with an excess of blasts type 2
por: Scorza, Carla Alexandra, et al.
Publicado: (2023)

Lenalidomide Plus Decitabine Treatment in a Myelodysplastic Syndrome Patient With Deletion 5q and Excess Blasts
por: Serin, Istemi, et al.
Publicado: (2020)

Modulation of the Immune Response by Deferasirox in Myelodysplastic Syndrome Patients
por: Votavova, Hana, et al.
Publicado: (2021)

Linking aberrant glycosylation of plasma glycoproteins with progression of myelodysplastic syndromes: a study based on plasmonic biosensor and lectin array
por: Chrastinová, Leona, et al.
Publicado: (2023)

Additional information offered by single nucleotide polymorphism array advantages in two myelodysplastic syndromes with excess blasts cases and future perspectives
por: Noronha, Thiago Rodrigo de, et al.
Publicado: (2019)

The Effect of Reagents Mimicking Oxidative Stress on Fibrinogen Function
por: Štikarová, Jana, et al.
Publicado: (2013)

Tryptophan Metabolism, Inflammation, and Oxidative Stress in Patients with Neurovascular Disease
por: Hajsl, Martin, et al.
Publicado: (2020)

Fibrin Clot Formation under Oxidative Stress Conditions
por: Kaufmanova, Jirina, et al.
Publicado: (2021)

Evolution of chronic myelomonocytic leukemia from refractory anemia: the unusual course of a myelodysplastic syndrome
por: Niscola, Pasquale, et al.
Publicado: (2013)

Genetic alterations in Thai adult patients with acute myeloid leukemia and myelodysplastic syndrome—excess blasts detected by next-generation sequencing technique
por: Owattanapanich, Weerapat, et al.
Publicado: (2021)

Circulating Small Noncoding RNAs Have Specific Expression Patterns in Plasma and Extracellular Vesicles in Myelodysplastic Syndromes and Are Predictive of Patient Outcome
por: Hrustincova, Andrea, et al.
Publicado: (2020)

Five‐day regimen of azacitidine for lower‐risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single‐arm phase 2 trial
por: Morita, Yasuyoshi, et al.
Publicado: (2018)

Identification of Plasma Thrombopoietin Level and Its Significance in Patients with Aplastic Anemia and Myelodysplastic Syndrome
por: Zhang, Mengying, et al.
Publicado: (2023)

Focal blast crisis in concomitant myelodysplastic syndrome and chronic myelogenous leukemia
por: Reap, Leo, et al.
Publicado: (2020)

Prognostic impact of immunophenotypic aberrancies of blasts in lower risk myelodysplastic syndrome
por: Corrao, Kristen, et al.
Publicado: (2022)

Glutathione promotes the synergistic effects of venetoclax and azacytidine against myelodysplastic syndrome‑refractory anemia by regulating the cell cycle
por: Wang, Xiaobo, et al.
Publicado: (2023)

JAK2 V617F mutation in myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable, refractory anemia with ring sideroblasts with thrombocytosis, and acute myeloid leukemia
por: Jekarl, Dong Wook, et al.
Publicado: (2010)

Implications of the 5(th) Edition of the World Health Organization Classification and International Consensus Classification of Myeloid Neoplasm in Myelodysplastic Syndrome With Excess Blasts and Acute Myeloid Leukemia
por: Lee, Cheonghwa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nu3cbauqnnmhhcid3ri0bld33k